Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)
| Status: | Completed |
|---|---|
| Conditions: | Ovarian Cancer, Women's Studies |
| Therapuetic Areas: | Oncology, Reproductive |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 4/17/2018 |
| Start Date: | March 2014 |
| End Date: | November 20, 2016 |
Targeting Pathophysiologic Pathways in Polycystic Ovary Syndrome Using a Response to Metformin Phenotype
The investigator's global hypothesis is that women with Polycystic Ovary Syndrome (PCOS) can
be separated into subtypes based on their response to metformin. The investigators propose
here to use both targeted and non-targeted metabolomic approach to identify pathways
associated with metformin's effect on insulin sensitivity and endothelial function. This
pilot project will be the foundation for developing tailored therapeutic approaches to
Polycystic Ovary Syndrome and identifying novel drug targets.
be separated into subtypes based on their response to metformin. The investigators propose
here to use both targeted and non-targeted metabolomic approach to identify pathways
associated with metformin's effect on insulin sensitivity and endothelial function. This
pilot project will be the foundation for developing tailored therapeutic approaches to
Polycystic Ovary Syndrome and identifying novel drug targets.
The investigators propose to use both targeted and non-targeted metabolomic approaches to
identify pathways associated with metformin's effect on insulin sensitivity, weight,
androgens and endothelial function. This project will be the foundation for developing
tailored therapeutic approaches to Polycystic Ovary Syndrome and identifying novel drug
targets. This pilot project is intended to inform the development of hypothesis and specific
aims for a future grant application to National Institutes of Health (NIH).
identify pathways associated with metformin's effect on insulin sensitivity, weight,
androgens and endothelial function. This project will be the foundation for developing
tailored therapeutic approaches to Polycystic Ovary Syndrome and identifying novel drug
targets. This pilot project is intended to inform the development of hypothesis and specific
aims for a future grant application to National Institutes of Health (NIH).
Inclusion Criteria:
- Body mass index (BMI) greater than or equal to 25
- Polycystic Ovary Syndrome criteria of both oligomenorrhea (<9 menses per year) and
androgen excess [clinical hirsutism (Ferriman-Gallway score >8 or severe acne) or
elevated testosterone].
- Taking no medications for the treatment of insulin resistance.
Exclusion Criteria:
- Diagnosis of Cushing's syndrome
- Untreated hypo/hyperthyroidism
- Elevated prolactin
- Congenital adrenal hyperplasia
- Renal insufficiency (creatinine > 1.5)
- Diabetes
- Medications that can significantly affect endothelial function
- Pregnancy
- Breast Feeding
- Taking oral contraceptives
- Currently smoking
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Alice Y Chang, MD
Phone: 507-293-5580
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
